8-K current report · filed Nov 13, 2026

Incyte (INCY) 8-K Current Report: November 13, 2026

Item 8.01INCY overview

Short answer

Incyte (INCY) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 8.01 (Other Events). Phase 3 MAESTRA-3 ovarian cancer study canceled before planned fourth-quarter 2026 start.

Incyte 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Phase 3 MAESTRA-3 ovarian cancer study canceled before planned fourth-quarter 2026 start
  • INCB123667 development continues without safety or efficacy concerns cited
  • Portfolio prioritization shifts resources away from bevacizumab combination maintenance therapy
  • No expected impact on financial guidance or previously disclosed long-term outlook

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Incyte 8-K filings

Get the next INCY 8-K as it lands

Follow INCY for push alerts, or ask the research agent what this filing means.